FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 273 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Making real change: 4 ways we’ve influenced cancer policy July 6, 2022 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... September 2, 2025 Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... May 12, 2021 What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials December 6, 2023 Load more HOT NEWS Race for Life events are back this autumn Today is Random Acts of Kindness Day Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with... Tables Turned
